Cenexi
About Cenexi
Cenexi is a company founded in 2004 by Philippe Mougin was acquired by Gland Pharma in November 2022.. Cenexi offers products and services including Sterile Dosage Forms, Non-Sterile Dosage Forms, and Development Services. Cenexi operates in a competitive market with competitors including Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
- Founders Philippe Mougin
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$492.01 K (USD), Grant
Sep 28, 2023
-
Investors
Gland Pharma
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Gland Pharma
(Nov 29, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cenexi
Cenexi offers a comprehensive portfolio of products and services, including Sterile Dosage Forms, Non-Sterile Dosage Forms, and Development Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Produces sterile products like ampoules and prefilled syringes for pharmaceuticals
Manufactures items such as tablets, capsules, and syrups for drug production
Offers expertise in pharmaceutical development and industrial transfer processes
Funding Insights of Cenexi
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $492,006
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Grant - Cenexi | Valuation |
investors |
|
| Feb, 2023 | Amount | Grant - Cenexi | Valuation |
investors |
|
| Jun, 2022 | Amount | Grant - Cenexi | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cenexi
Cenexi has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gland Pharma, European Union and Ministry of Economy, Finance and Industrial and Digital Sovereignty. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm specializing in markets and partnerships.
|
Founded Year | Domain | Location | |
|
Financial investment management services are provided by Indigo Capital.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cenexi
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cenexi
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cenexi Comparisons
Competitors of Cenexi
Cenexi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| domain | founded_year | HQ Location |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| domain | founded_year | HQ Location |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| domain | founded_year | HQ Location |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| domain | founded_year | HQ Location |
CDMO with a focus on early phase drug product development
|
|
| domain | founded_year | HQ Location |
Biopharma regulatory affairs, quality control, and strategy services are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cenexi
Frequently Asked Questions about Cenexi
When was Cenexi founded?
Cenexi was founded in 2004 and raised its 1st funding round 4 years after it was founded.
Who is the current CEO of Cenexi?
Philippe Mougin is the current CEO of Cenexi. They have also founded this company.
What does Cenexi do?
Cenexi was founded in 2004 as a pharmaceutical contract development and manufacturing organization. Services encompass pre-formulation studies and formulation development across dosage forms such as sterile and solid variants. Facilities have been approved by regulatory bodies including FDA, EMEA, PMDA, and ANVISA, supporting operations in the global pharmaceutical sector.
Who are the top competitors of Cenexi?
Cenexi's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
What products or services does Cenexi offer?
Cenexi offers Sterile Dosage Forms, Non-Sterile Dosage Forms, and Development Services.
Who are Cenexi's investors?
Cenexi has 5 investors. Key investors include Gland Pharma, European Union, Ministry of Economy, Finance and Industrial and Digital Sovereignty, Ardian, and Indigo Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.